Safe and widely applicable EGF for various ophthalmic wounds.
A state category I New Drug based on genetic engineering technology.
Repairs the cornea and accelerates the restoration of cornea function after eye surgeries, Proven to be safe and effective without any side effects.
Genesoft® has a competitive advantage of room temperature storage, allowing cheaper and easier transport and storage.
Since 2H2021, the Group has conducted direct sales of Genesoft® through its own stable and efficient team, which will significantly enhance the promotion ability.
Genesoft® can develop the new dosage form of BFS, with a huge potential market.
According to Frost & Sullivan, the global ophthalmic medicine market has grown from USD 24.7 billion in 2015 to USD 33.7 billion in 2019, with a compound growth rate of 8.0%. The overall market size of ophthalmology in China reached 170 billion yuan in 2019.
With the accelerated aging of China's population and the increasing popularity of ophthalmic surgery, it is expected that the compound growth rate of China's ophthalmic drug market will be close to 18% in the future, especially in the three major areas of fundus diseases, anti-infection and anti-inflammatory.
The BFS high-end production line has high production efficiency and precision, low comprehensive cost, and the single-dose packaging is for single use, which has the advantages of economy, safety and portability, and can further enhance the product penetration rate of Genesoft®.
